Metformin Ameliorates Treatment of Obese Type 2 Diabetic Patients with Mental Retardation; its Effects on Eating Behavior and Serum Leptin Levels

T. Komori; F. Yoshida; J. Nakamura; S. Miyazaki; H. Miura; A. Iguchi

doi:10.1055/s-2004-821187

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2004; 112(8): 422-428
DOI: 10.1055/s-2004-821187

Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Metformin Ameliorates Treatment of Obese Type 2 Diabetic Patients with Mental Retardation; its Effects on Eating Behavior and Serum Leptin Levels

T. Komori¹ ^, ² , F. Yoshida¹ ^, ² , J. Nakamura² , S. Miyazaki³ , H. Miura⁴ , A. Iguchi⁴

¹Department of Medicine, Aichi Human Service Center, Aichi, Japan
²The Third Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Aichi, Japan
³Department of Pediatric Neurology, Aichi Human Service Center, Aichi, Japan
⁴Department of Geriatric Medicine, Nagoya University School of Medicine, Nagoya, Aichi, Japan

Abstract

The metabolic effects of a biguanide, metformin, on glycemic control and eating behavior were investigated in 16 type 2 diabetic subjects with mental retardation who were habitual overeaters and had difficulty in controlling their appetites. The subjects (n = 16) received metformin (750 mg/day) for 6 months and body weight, body mass index (BMI) were measured monthly. They had repetitive metabolic and hormonal studies. Their eating behavior was analyzed by questionnaires given by their guardians before and after treatment. Metformin treatment significantly reduced their body weights (p < 0.01), body mass index (BMI) (p < 0.01), the levels of HbA1c (p < 0.001), fasting blood glucose (FBG) (p < 0.05), serum insulin (p < 0.05), C-peptide (p < 0.01), triglyceride (p < 0.01), and total cholesterol (p < 0.05). Insulin resistance index (FBG (mg/dl) × serum insulin levels (µU/ml) × 1/405) was significantly reduced after 1-month treatment. The serum leptin levels were significantly decreased after 4 month's treatment and thereafter (p < 0.05). Analysis of the questionnaires before and after treatment showed that the daily intake of regular and additional foods significantly decreased after treatment (p < 0.01 and p < 0.001, respectively) with improvements of eating behavior. We conclude that metformin may have beneficial effects not only to control glycemia but also to correct eating behavior in obese type 2 diabetic patients with the difficulty in controlling their appetites. The improvement was related to the reduction of insulin resistance and serum leptin levels.

Key words

Type 2 diabetes - obesity - biguanides - metformin - leptin

Full Text

References

1 Bailey C J, Turner R C. Metformin. New Engl J Med. 1996; 334 574-579
2 Borst S E, Snellen H G, Lai H L. Metformin treatment enhances insulin-stimulated glucose transport in skeletal muscle of Sprague-Dawley rats. Life Sci. 2000; 67 165-174
3 Caprio S, Tamborlane W, Silver D, Robinson C, Leibel R, McCarthy S, Grozman A, Belous A, Maggs D, Sherwin R S. Hyperleptinemia: an early sign of juvenile obesity. Relations to body fat depots and insulin concentrations. Am J Physiol. 1996; 271 E626-630
4 Carlsen S M, Grill V, Folling I. Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease. Diab Res Clin Pract. 1998; 39 47-54
5 Clement K, Garner C, Hager J, Philippi A, LeDuc C, Carey A, Harris T J, Jury C, Cardon L R, Basdevant A, Demenais F, Guy-Grand B, North M, Froguel P. Indication for linkage of the human OB gene region with extreme obesity. Diabetes. 1996; 45 687-690
6 Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte J M, Basdevant A, Bougneres P, Lebouc Y, Froguel P, Guy-Grand B. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998; 392 398-401
7 DeFronzo R A, Goodman A M. et al . Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. New Engl J Med. 1998; 333 541-549
8 Gielkens H A, Verkijk M, Lam W F, Lamers C B, Masclee A A. Effects of hyperglycemia and hyperinsulinemia on satiety in humans. Metabolism. 1998; 47 321-324
9 Gunay-Aygun M, Cassidy S B, Nicholls R D. Prader-Willi and other syndromes associated with obesity and mental retardation. Behav Genet. 1997; 27 307-324
10 Hattori A, Uemura K, Miura H, Ueda M, Iguchi A. Gender-related difference in relationship between insulin resistance and serum leptin level in Japanese type 2 diabetic subjects. Endocr J. 2000; 47 615-621
25 Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002; 360 (9326) 7-22
11 Kellerer M, Lammers R, Fitshe A, Haring H U. Insulin inhibits leptin receptor signaling in HEK293 cells at the level of jauns kinase-2: a potential mechanism for hyperinsulinemia-associated leptin resistance. Diabetologia. 2001; 44 1125-1132
12 Lee A, Morley J E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998; 6 47-53
13 Lee A J. Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy. 1996; 16 327-351
14 Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia. . 1999; 42 406-412
15 Maruhama Y, Abe R, Okuguchi F, Ohneda A. Dietary intake and hyperlipidemia in controlled diabetic outpatients. Diabetes. 1997; 26 94-99
16 Matsumoto K, Miyake S, Yano M, Ueki Y, Yamaguchi Y, Akazawa S, Tominaga Y. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care. 1997; 20 1562-1568
17 Paolisso G, Amato L, Eccellente R, Gambardella A, Tagliamonte M R, Varricchio G, Carella C, Giugliano D, D'Onofrio F. Effect of metformin on food intake in obese subjects. Europ J of Clin Invest. 1998; 28 441-446
18 Patane G, Piro S, Rabuazzo A M, Anello M, Vigneri R, Purello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes. 2000; 49 735-740
19 Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Staels B, Auwerx J. Transient increase in obese gene expression after food intake or insulin administration. Nature. 1995; 377 527-529
20 Solomon S S, Mishra S K, Cwik C, Rajanna B, Postlethwaite A E. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab Res. 1997; 29 379-382
21 Tommis A D. Diabetes. Br Med Bull. 2001; 59 159-172
22 Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich J E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. New Engl J Med. 1995; 333 550-554
23 Prospective Diabetes Study Group U K(UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS). Lancet. 1998; 352 854-865
24 Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature. 1998; 393 684-688

M. D. Futoshi Yoshida

Central Hospital
Aichi Human Service Center

713 - 8 Kamiya-cho, Kasugai-shi

Aichi 480-0392

Japan

Phone: + 81568880811

Fax: + 81 5 68 88 08 24

Email: motoes0331@yahoo.co.jp